Parabilis Medicines, Inc.
PBLSHealthcare|Biotechnology|US
$28.53
+0.65 (+2.33%)
Tangible Book / Share
$36.24
Cash / Share
$38.77
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05919264 FOG-001 in Locally Advanced or Metastatic Solid Tumors | Cancer, Colorectal Cancer | P1P2 | Recruiting | 619 | Open-label | FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab, FOG-001 |